Long-Acting Injectable (LAI) Technologies: Stabilized Injectable Formulation (SIF), a sustained-release drug delivery platform
Our proprietary SIF, LAI drug delivery technologies enables us to develop
differentiated, ready-to-use, long-acting injectable products through 505(b)(2) or
505(b)(1) regulatory pathways.
To date, the SIF platform has demonstrated its applications to complex small molecules and peptides, and proven it’s technological and commercial value through Foresee's approved and launched product CAMCEVI®. Products currently under development are FP-014 (Triptorelin, for prostate cancer), FP-016 (neurology / psychiatry), FP-017 (neurology / psychiatry), and other products at earlier stage and others not currently core to our portfolio strategy.
To date, the SIF platform has demonstrated its applications to complex small molecules and peptides, and proven it’s technological and commercial value through Foresee's approved and launched product CAMCEVI®. Products currently under development are FP-014 (Triptorelin, for prostate cancer), FP-016 (neurology / psychiatry), FP-017 (neurology / psychiatry), and other products at earlier stage and others not currently core to our portfolio strategy.
SIF LAI Delivery Systems
Modular Technology Approach – Flexibility for Ideal Complex Drug Candidates
- Biodegradable polymer-based
- Industry leading approach in the space of complex, unstable products
- Commercially-proven with Camcevi® product
- Proprietary combination of biocompatible lipids
- Lipids approved for human use with well-established safety and toxicity profiles
- Permits high drug loading up to 65% w/w
- Combined solutions-based delivery system
- Proprietary combination of GRAS agents
- Simplified manufacturing process
- Emerging undisclosed delivery system